News China Medical System Holdings Limited

Equities

867 KYG211081248

Delayed Hong Kong S.E. Other stock markets 11:59:42 2024-05-20 pm EDT			5-day change	1st Jan Change
7.12 ^HKD	-2.06%		-4.56%	-48.55%

May. 09	China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
Apr. 23	China Medical System's Anti-Anaemia NDA Accepted in China	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Final dividend	May. 12	FA
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	May. 09	CI
China Medical System: New Drug Application of Desidustat Tablets Accepted in China	Apr. 23	AQ
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	Apr. 23	CI
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
China Medical System Registers New Vitiligo Drug in Macau	Apr. 16	MT
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	Apr. 02	CI
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia	Apr. 01	AQ
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs	Mar. 27	AQ
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	Mar. 27	CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	Mar. 19	MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	Mar. 19	CI
China Medical System Obtains Nod For Trials of Two Drugs	Feb. 08	MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	Feb. 07	CI
China Medical Gains License to Sell Kidney Disease Drug Across China	Feb. 05	MT
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®	Feb. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News China Medical System Holdings Limited

Equities

867

KYG211081248

Summary

Filters